Patricia Natividad

Patricia Natividad supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing mission-critical procurement activities that sustain the agency’s regulatory science infrastructure. She manages acquisitions for high-precision analytical instrumentation, laboratory equipment maintenance, and scientific consulting services essential to drug safety evaluation and medical device validation. Her work directly enables the FDA’s public health mission by ensuring access to cutting-edge analytical capabilities and reliable technical support for regulatory decision-making. She routinely handles complex, technically demanding contracts under FAR Part 15, often involving specialized scientific and engineering requirements. Natividad maintains strategic relationships with a focused group of contractors specializing in clinical research support, toxicological pathology, and pharmaceutical development services. Key partners include Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., reflecting a preference for niche vendors with deep domain expertise in FDA-regulated environments. Her contracting patterns emphasize long-term, performance-based partnerships that ensure continuity in critical testing and analytical workflows, often requiring compliance with Good Laboratory Practices (GLP) and 21 CFR Part 11 standards. Her procurement strategy prioritizes small business participation, with over 63% of awards set aside for small businesses under FAR 19.5, demonstrating a strong commitment to socioeconomic contracting goals. While the majority of contracts are small business set-asides, she also engages 8(a) certified firms, reflecting a deliberate effort to foster diversity in the supplier base and expand access to innovative, agile service providers in regulated environments. Natividad’s technical focus centers on NAICS 334516 (Analytical Laboratory Instrument Manufacturing), where she procures mass spectrometers, chromatography systems, and other high-end analytical equipment vital to drug purity and stability testing. She also manages maintenance contracts under NAICS 811210 and selects management consultants under NAICS 541611 to optimize procurement processes. Her expertise lies at the intersection of regulatory science, laboratory operations, and technical procurement, ensuring the FDA’s infrastructure remains aligned with evolving public health demands.